U.S. FDA· @FDA · X·· 2 小时前精选AI 评分62
AI 导读
FDA 发布新的透明度路线图，列出 FY26 里程碑与 FY27 优先事项，涵盖 CRL 披露、NAMs、食品标签、检查等方向。FDA 称透明度既是良好治理，也是加速创新和保护公共健康的方式。
推荐理由
FDA 公布透明度路线图，列出 FY26 里程碑与 FY27 优先事项，可了解其监管信息公开的推进方向。
正文
Transparency isn't just good government — it's how we accelerate innovation and protect public health. Today, FDA released its new Transparency Roadmap, outlining FY26 milestones and FY27 priorities: CRL disclosure, NAMs, food labeling, inspections, and more. https://www.fda.gov/news-events/fda-voices/transparency-makes-modern-regulatory-science-stronger-fdas-transparency-roadmap
来源：U.S. FDA · x.com